VOR — Vor Biopharma Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1817229 ·
Last close
$18.18
Market Cap
$1.12B
52W High
$26.00
52W Low
$6.50
ADV30
772,625
Next earnings
2026-10-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -58,444,000 | -86,727,000 | 496,312,000 | 78,977,000 | 633,485,000 |
| Jun 2026 | 0 | — | -47,853,000 | -62,810,000 | 481,053,000 | 107,855,000 | 681,250,000 |
| Mar 2026 | 0 | — | -35,160,000 | -219,585,000 | 506,746,000 | 169,873,000 | 657,170,000 |
| Dec 2025 | 0 | — | -35,960,000 | 1,722,858,000 | 464,126,000 | 396,486,000 | 628,438,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-140,087,000
Investing CF
$-348,989,000
Financing CF
$404,112,000
CapEx
$-726,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-379.14
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,435,367,000
Inventory
—
Receivables
—
ST Investments
$358,274,000
EBIT TTM
$-147,080,000
Pretax Income TTM
$627,779,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -371,642,000 | -695,981,000 | 464,126,000 | 628,438,000 | -164,312,000 | -142,713,000 |
| Dec 2024 | 0 | -121,185,000 | -116,914,000 | 142,891,000 | 46,227,000 | 96,664,000 | -99,660,000 |
| Dec 2023 | 0 | -126,036,000 | -117,863,000 | 198,126,000 | 47,402,000 | 150,724,000 | -100,292,000 |
| Dec 2022 | 0 | -93,418,000 | -92,094,000 | 299,366,000 | 48,759,000 | 250,607,000 | -85,144,000 |
TTM Snapshot
Revenues TTM
$12,804,000
NetIncome TTM
$627,779,000
OpCashFlow TTM
—
Assets (Latest)
$481,053,000
Forward EPS
$-3.67
Max Pain — expiry 2027-05-21
max pain strike: $20.00 · spot: $17.83 · call oi: 3,389 · put oi: 422
Expected Move to 2027-05-21:
±$12.95
(72.63%) —
implied range
$4.88 –
$30.78
· ATM straddle on $17.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INBX | Inhibrx Biosciences, Inc. | $1.09B | $74.18 | — |
| IMTX | Immatics N.V. | $957.50M | $6.29 | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.30B | $4.00 | — |
| NVAX | NOVAVAX INC | $1.31B | $7.96 | — |
| ODTX | Odyssey Therapeutics, Inc. | $931.07M | $19.37 | — |
News headlines (Yahoo Finance, 1h cache)
Is Narrower Quarterly Loss Altering The Investment Case For Vor Biopharma Stock?
2026-11-13 02:15 · Yahoo
Vor Biopharma Adds RC298 to RemeGen License Deal
2026-11-12 15:44 · Yahoo
Vor Bio To Participate in 2026 Jefferies Global Healthcare Conference
2026-11-10 13:00 · Yahoo
Vor Biopharma (VOR) Stock Looks Reasonable After a 94% Five Year Slide
2026-11-06 21:11 · Yahoo
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-04 21:15 · Yahoo
Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus
2026-10-08 15:17 · Yahoo
Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)
2026-10-04 16:05 · Yahoo
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
2026-09-08 11:00 · Yahoo
Vor Bio To Participate in Upcoming September Conferences
2026-09-01 12:00 · Yahoo
Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise
2026-11-12 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.